Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 8/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623026 | 0.86 | SYK (0.44) | GRM5EGFRBTK | |
| SCHEMBL1025446 | 0.83 | BCL6 (0.38) | GRM5EGFRPIN1BTKCTSC | |
| SCHEMBL1082854 | 0.82 | EGFR (0.38) | EGFRPIN1BTKJAK2CTSC | |
| SCHEMBL1024611 | 0.77 | MEN1 (0.49) | EGFRBTK | |
| SCHEMBL4348221 | 0.77 | ALDH1A1 (0.46) | EGFRBTKJAK2TYK2CTSC | |
| SCHEMBL1024609 | 0.77 | MEN1 (0.49) | EGFRBTK | |
| SCHEMBL4335022 | 0.76 | BTK (0.42) | EGFRBTKCTSC | |
| SCHEMBL1024930 | 0.76 | FFAR1 (0.43) | GRM5PTPN11PDGFRBKDRJAK2 | |
| SCHEMBL1026707 | 0.76 | MEN1 (0.49) | EGFR | |
| SCHEMBL4716464 | 0.76 | PTPN11 (0.52) | GRM5PTPN11PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | GRM5 2685/4885EGFR 180/4885PTPN11 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.